Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Affiliation

Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Neurology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. Electronic address: [Email]

Abstract

We have previously shown that cannabidiol (CBD; Epidiolex®) significantly affects levels of clobazam/N-desmethylclobazam, rufinamide, topiramate, zonisamide, and eslicarbazepine. In the present study, we tested whether the presence of concomitant clobazam affected seizure frequency and severity (treatment response) 12 weeks after initiation of therapy with CBD in patients with treatment-resistant epilepsy (TRE). The secondary questions were whether the presence of any of the other antiepileptic drugs (AEDs) had an effect on seizure frequency or severity at 12, 24, or 48 weeks after therapy initiation.

Keywords

Antiepileptic drugs,Cannabidiol,Clobazam,Drug interactions,Treatment-resistant epilepsy,

OUR Recent Articles